Axial Spondyloarthritis - Pipeline Review, H1 2020

May 2020 | 251 pages | ID: A24DA28C120EN
Global Markets Direct

Abstracts

Axial Spondyloarthritis - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Axial Spondyloarthritis – Pipeline Review, H1 2020, provides an overview of the Axial Spondyloarthritis (Musculoskeletal Disorders) pipeline landscape.

Axial spondylitis is a type of inflammatory arthritis involving the spine and/or sacroiliac joints. Axial spondylitis is strongly related to the presence of the HLA-B27 gene. A genetic test for HLA-B27 is available.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Axial Spondyloarthritis – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Axial Spondyloarthritis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Axial Spondyloarthritis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Axial Spondyloarthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 9, 8, 3, 10, 1, 18 and 7 respectively.

Axial Spondyloarthritis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Axial Spondyloarthritis (Musculoskeletal Disorders).
• The pipeline guide reviews pipeline therapeutics for Axial Spondyloarthritis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Axial Spondyloarthritis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Axial Spondyloarthritis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Axial Spondyloarthritis (Musculoskeletal Disorders)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Axial Spondyloarthritis (Musculoskeletal Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Axial Spondyloarthritis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Axial Spondyloarthritis - Overview
Axial Spondyloarthritis - Therapeutics Development
Axial Spondyloarthritis - Therapeutics Assessment
Axial Spondyloarthritis - Companies Involved in Therapeutics Development
Axial Spondyloarthritis - Drug Profiles
Axial Spondyloarthritis - Dormant Projects
Axial Spondyloarthritis - Discontinued Products
Axial Spondyloarthritis - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Axial Spondyloarthritis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Axial Spondyloarthritis - Pipeline by 3SBio Inc, H1 2020
Axial Spondyloarthritis - Pipeline by AbbVie Inc, H1 2020
Axial Spondyloarthritis - Pipeline by Akeso Inc, H1 2020
Axial Spondyloarthritis - Pipeline by Alvotech ehf, H1 2020
Axial Spondyloarthritis - Dormant Projects, H1 2020
Axial Spondyloarthritis - Dormant Projects, H1 2020 (Contd..1), H1 2020
Axial Spondyloarthritis - Dormant Projects, H1 2020 (Contd..2), H1 2020
Axial Spondyloarthritis - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Axial Spondyloarthritis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

3SBio Inc
AbbVie Inc
Akeso Inc
Alvotech ehf
Amgen Inc
AstraZeneca Plc
Beijing Eastern Biotech Co Ltd
Bio-Thera Solutions Ltd
Biocad
Biocon Ltd
BioXpress Therapeutics SA
Clover Biopharmaceuticals
DNX Biopharmaceuticals Inc
Eli Lilly and Co
FunPep Co Ltd
Galapagos NV
Hengenix Biotech Inc
Huabo Biopharm Co Ltd
Hualan Biological Engineering Inc
Iltoo Pharma
Immunwork Inc
Innovent Biologics Inc
InSight Biopharmaceuticals Ltd
Izana Bioscience Ltd
Jiangsu Hengrui Medicine Co Ltd
JiangSu Qyuns Therapeutics Co Ltd
Lupin Ltd
Luye Pharma Group Ltd
Mabpharm Ltd
Mycenax Biotech Inc
NeuClone Pty Ltd
Nichi-Iko Pharmaceutical Co Ltd
Nimbus Therapeutics LLC
Novartis AG
Pfizer Inc
Pharmapraxis
RNAx Ltd
Roivant Sciences Ltd
Shandong Danhong Pharmaceutical Co Ltd
Shanghai Junshi Bioscience Co Ltd
Siam Bioscience Co Ltd
Sichuan Haisco Pharmaceutical Co Ltd
Sino Biopharmaceutical Ltd
siRNAgen Therapeutics Corp
Sun Pharma Advanced Research Company Ltd
Wuhan Institute of Biological Products Co Ltd
Xbrane Biopharma AB